Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
38 hedge funds and large institutions have $45.3M invested in Genocea Biosciences, Inc. in 2014 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
12% less funds holding
Funds holding: 43 → 38 (-5)
22% less capital invested
Capital invested by funds: $58.1M → $45.3M (-$12.7M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
+$608K |
| 2 |
DM
Deerfield Management
New York
|
+$427K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$258K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$128K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$487K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$141K |
| 3 |
JP Morgan Chase
New York
|
-$124K |
| 4 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$102K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$49.5K |
GNCA Hedge Fund Activity: Q4 2014 in Review
38 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q4 2014, worth a combined $45.3M — down 22% from $58.1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GNCA and 3 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 13 added.
The largest buyer was Axa, adding an estimated $608K. The largest seller was Wellington Management Group, cutting an estimated $487K.
- 38 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q4 2014, down from 43 in Q3 2014.
- Funds reported $45.3M of Genocea Biosciences, Inc. stock for Q4 2014, down 22% quarter-over-quarter.
- 3 funds opened new Genocea Biosciences, Inc. positions in Q4 2014 and 6 closed out, a net change of -3 holders.
- The largest Genocea Biosciences, Inc. buyer in Q4 2014 was Axa, an estimated $608K added.
- The largest Genocea Biosciences, Inc. seller in Q4 2014 was Wellington Management Group, an estimated $487K sold.
Based on aggregated 13F filings for Q4 2014.